0.04 g =____mg (Fill in the blank with the numerical value only)

A. 100 mg:. The label clearly states that each capsule contains 25 mg of Indomethacin. There is no indication that multiple capsules are taken at once unless prescribed, so 100 mg is incorrect for a single capsule dosage.
B. 125 mg: This is not the indicated dose per capsule.
C. 25 mg: The label clearly indicates that each capsule contains 25 mg of Indomethacin. This is the correct dosage per capsule. Indomethacin is often available in 25 mg increments for safe titration and individualized dosing based on patient need.
D. 75 mg: While 75 mg is a common dosage form for some extended-release Indomethacin preparations, this particular label shows 25 mg immediate-release capsules. There is no mention of 75 mg on the drug label in this case.

A. Advise the patient to continue using the nasal decongestant but reduce the frequency to once daily: Continued use, even at a reduced frequency, may not resolve the underlying issue. Prolonged use of topical nasal decongestants can lead to rebound congestion (rhinitis medicamentosa), which won't improve without discontinuation.
B. Suggest increasing the dosage of the current nasal decongestant to manage congestion: Increasing the dosage worsens rebound congestion and the dependence cycle. Higher doses can also raise the risk of systemic side effects such as elevated blood pressure or tachycardia.
C. Educate the patient on discontinuing the nasal decongestant and recommend a saline nasal spray for symptom relief: This is the most appropriate intervention. Rebound congestion is best managed by stopping the decongestant. Saline sprays help moisturize nasal passages and reduce symptoms safely during withdrawal.
D. Prescribe a stronger nasal decongestant to alleviate symptoms more effectively: A stronger formulation would likely exacerbate the problem. The key to managing rhinitis medicamentosa is breaking the cycle of decongestant overuse, not intensifying it.